Cytokinetics, Incorporated has announced the appointment of James M. Daly to its Board of Directors, effective August 19, 2025. Daly brings over 30 years of experience in the biopharmaceutical industry, with a focus on commercialization. He has previously held senior leadership roles at Incyte Corporation and Amgen.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.